探索潜在的抑制剂,以对抗人类非洲三体病的各种酶性标
Sayandeep Brahma1, Susmita Moitra1, Soumya Ranjan Bagchi2,3
1Cell and developmental biology special, Department of Zoology, University of Kalyani, Kayani, Nadia- 741235, India.
Combinatorial chemistry & high throughput screening
|April 27, 2024
概括
新型药物标和多标抑制剂对于对抗人类非洲三虫病 (HAT) 至关重要. 本综述探讨了潜在的酶性标和化合物,包括阿科齐博罗尔和费克西尼达,以克服耐药性并改善HAT治疗.
科学领域:
- * 寄生虫学和热带医学
- * 药用化学与药物发现
背景情况:
- *目前人类非洲三虫病 (HAT) 治疗面临的挑战包括毒性,可变的疗效和新兴药物耐药性.
- *寄生虫Trypanosoma brucei依赖于特定的酶性点来生存和繁殖.
研究的目的:
- * 审查Trypanosoma brucei中潜在的酶标,以开发新的HAT药物.
- * 探索用于HAT治疗的新型合成和天然化合物,包括多位抑制剂.
- * 确定有希望的治疗候选者来克服药物耐药性.
主要方法:
- * 对Trypanosoma brucei潜在的酶性点进行了全面的文献综述.
- *分析小分子,包括囊蛋白酶和热冲击蛋白,作为药物点.
- * 评估现有和新型化合物,如阿科齐博罗尔和费克辛达的疗效和毒性.
主要成果:
- *确定了关键的酶性标:氨酸蛋白酶,HSP-90,TR,Farnesyl二酸盐合成酶,葡萄糖-6-酸盐脱酶,UP-4-银酸盐表酶,和氨酸三酸盐合成酶.
- *强调了囊蛋白酶和热冲击蛋白作为关键点的潜力.
- * 提出了一份合成,天然和多位抑制剂清单,包括阿科齐博罗尔和费克西尼达.
结论:
- *针对Trypanosoma brucei中的特定酶的新型抑制剂对于开发有效的HAT疗法至关重要.
- * 多位抑制剂提供了一种有前途的策略来对抗HAT的耐药性.
- *进一步研究连接物修饰和化合物疗效对于推进HAT治疗至关重要.
相关概念视频
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
Enzyme Inhibition
78.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.3K


